欢迎来到《四川大学学报(医学版)》

溴隐亭治疗男性泌乳素腺瘤及对患者性功能影响的评价

Effects of Bromocriptine on the Treatment of Prolactinomas in Male Patients and its Influences on Their Sexual Function

  • 摘要: 目的 探讨溴隐亭对男性泌乳素腺瘤患者的治疗效果及性功能的影响。 方法 分析及随访29例男性泌乳素腺瘤患者采用溴隐亭治疗后不同时间内分泌学、影像学检测的变化,并采用国际勃起功能指数-5(IIEF-5)对患者在药物治疗前、后的性功能进行评估。 结果 男性泌乳素腺瘤患者临床表现以性功能障碍、头痛、视力障碍多见。溴隐亭治疗6个月后,患者临床症状改善明显;血清泌乳素(PRL)水平明显下降(P<0.05),睾酮(T)水平有所升高(P<0.05),总体PRL水平正常化率为82.8%;疗效评价全部患者均有不同程度缓解,药物治疗总体有效率达100%;按照IIEF-5评估,患者性功能障碍均有不同程度改善。 结论 溴隐亭能改善患者临床症状,使内分泌功能趋于正常,更重要的是明显改善患者的性功能障碍状况。

     

    Abstract: Objecitve To explore the effect of bromocriptine in the treatment of male patients with prolactinoma and its impacts on their sexual function. Methods The clinical data of 29 male patients with prolactinomas treated with Bromocriptine were analysed, International Index of Erectile Function-5 (IIEF-5) was used to assess the sexual function of married patients before and after the treatment of Bromocriptine. Results The main clinical symptoms of male patients with prolactinomas were sexual dysfunction, headache and hypopsia, which were released significantly at 6 months after Bromocriptine therapy, with the decrease of serum prolactin (PRL) level (P<0.05)and the improvement of basal testosterone (T) level (P<0.05). The total normalization rate of PRL was 82.8%, and total effective rate of Bromocriptine therapy was 100%. According to the assessment of IIEF-5, all the male patients had their sexual function improved in various degree. Conclusion Bromocriptine can improve the clinical symptoms of male patients with prolactinoma and their sexual function.

     

/

返回文章
返回